President and Chief Executive Officer · Adverum Biotechnologies, Inc. (ADVM)

Laurent Fischer

A named executive officer of Adverum Biotechnologies in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$4,131,290

Salary $691,795Stock awards $171,363

FY2023: $1,546,477

1st of 5 named executive officers at Adverum Biotechnologies by FY2024 total.

5 named officers on file for Adverum Biotechnologies, FY2024

Laurent Fischer’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • ADVM’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adverum Biotechnologies’s whole pay program stands against its peers

  • Adverum Biotechnologies’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADVM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Laurent Fischer’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Laurent Fischer compensation by year

Adverum Biotechnologies Summary Compensation Table · all 3 fiscal years held
In US dollars, as Adverum Biotechnologies reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$645,800$671,600$691,795
Bonus$0$0$0
Stock awards$0$0$171,363
Option awards$1,929,411$530,193$2,839,252
Non-equity incentive$329,358$342,531$415,080
Pension and deferred compensation$0$0$0
All other$2,070$2,153$13,800
Total$2,906,639$1,546,477$4,131,290

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adverum Biotechnologies, Inc. DEF 14A filed April 28, 2025, accession 0001140361-25-016005, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Adverum Biotechnologies, Inc. filed document, accession 0001140361-25-016005. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.

$2.9M
$1.5M
$4.1M
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU45,333$211,705—
Option200,000—$7.15
Option110,420—$19.90
Option52,313—$7.50
Option16,876—$10.90
Option10,500—$12.90
Option18,375—$12.90
Option2,840—$134.40

Per the Outstanding Equity Awards at Fiscal Year-End table in Adverum Biotechnologies, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

35 Form 4 lines since the FY2024 proxy (filed April 28, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-12-09Grant or award—500,000$0.00522,666
2025-12-09Exercise or conversion—150,000$4.20351,513
2025-12-09U—351,513—0
2025-12-09U—25,000—0
2025-12-09U—522,666—0
2025-12-09Disposition to the issuer derivative—93,000—0
2025-12-09Disposition to the issuer derivative—200,000—0
2025-12-09Exercise or conversion derivative—150,000—0

The 8 most recent of 35 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Adverum Biotechnologies’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Laurent Fischer · this pagePresident and Chief Executive Officer$4,131,290
Kishor SoparkarChief Operating Officer$1,843,178
Linda RubinsteinChief Financial Officer$1,605,925
Setareh SeyedkazemiChief Development Officer$1,598,442
Rabia OzdenChief Medical Officer$1,305,133

Board service

Adverum Biotechnologies board · FY2024

How this board is paid

Company policy: Adverum Biotechnologies pays directors a $40,000 cash retainer. As stated in Adverum Biotechnologies's FY2024 proxy.

The full Adverum Biotechnologies compensation record

free company brief

This page is one person within Adverum Biotechnologies's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adverum Biotechnologies proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adverum Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Laurent Fischer's compensation dossier · One-time report. No refunds.